Influence of sex and age on fluorouracil clearance

Journal of Clinical Oncology

Volumn 10, Issue 7, 1992, Pages 1171-1175

  Milano, G ^a   Etienne, M C ^a   Cassuto Viguier, E ^a   Thyss, A ^a   Santini, J ^a   Frenay, M ^a   Renee, N ^a   Schneider, M ^a   Demard, F ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; COVARIANCE; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMAN; MALE; MIDDLE AGE; NORMAL DISTRIBUTION; SEX CHARACTERISTICS;

EID: 0026636184     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1992.10.7.1171     Document Type: Article

References (28)

1. Grem JL: Fluorinated pyrimidines, in Chabner BA, Collins JM (eds): Cancer Chemotherapy, Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 180-225
2. Dreyfuss AI, Clark JR, Wright JE, et al: Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Int Med 112:167-172, 1990
3. Yokes EE, Schilsky RL, Weichselbaum RR, et al: Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: A clinical and pharmacological analysis. J Clin Oncol 8:214-247, 1990
4. Vokes EE, Vijayakumar S, Hoffman PC, et al: 5-fluorouracil with oral leucovorin and hydroxyurea and concomitant radiother-apy for stage III non-small cell lung cancer. Cancer 66:437-442, 1990.
5. Swain SM, Lippman ME, Egan EG, et al: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:890-899, 1989
6. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 16:215-237, 1989
7. Goldberg JA, Kerr DJ, Willmott N, et al: Pharmacokinetics and pharmacodynamics of locoregional 5-fluorouracil in advanced colorectal liver metastases. Br J Cancer 57:186-189, 1988
8. Van Groeningen CH, Pinedo HM, Heddes J, et al: Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48:6956-6961, 1988
9. Thyss A, Milano G, Renee N, et al: Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16:64-66, 1986
10. Milano G, Roman P, Khater R, et al: Dose versus pharmacokinetics for predicting tolerance for 5-day continuous infusion of 5-FU. Int J Cancer 41:537-541, 1988
11. Breimer DD: Variability in human drug metabolism and its implications. Int J Clin Pharm Res 3:399-413, 1983
12. Santini J, Milano G, Thyss A, et al: 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287-290, 1989
13. Christophidis N, Mihaly G, Vadja F, et al: Comparison of liquid-and-gas liquid Chromatographic assays of 5-fluorouracil in plasma. Clin Chem 25:83-86, 1979
14. Floyd RA, Hornbeck CL, Byfield JE, et al: Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. Drug Intell Clin Pharm 16:665-667, 1982
15. Petit E, Milano G, Levi R, et al: Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48:1676-1679, 1988
16. Harris BE, Song R, Song SJ, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma levels in cancer patients receiving 5-fluorouracil by protracted infusion. Cancer Res 50:197-201, 1990
17. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51, 1988
18. Tuchman M, Stoeckeler JS, Kiang DT, et al: Familial pyrimidinemia and pyriminuria associated with severe fluorouracil toxicity. New Engl J Med 313:245-249, 1985
19. Vestal RE, Wood AJJ: Influence of age and smoking on drug kinetics in man. Studies using model compounds. Clin Pharmacokinet 5:309-319, 1980
20. Durnas C, Loi CM, Cusack BJ: Hepatic drug metabolism and aging. Clin Pharmacokinet 19:359-389, 1990
21. Boublil JL, Milano G, Khater R, et al: Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: Pharmacokinetic evaluation. Br J Cancer 52:15-20, 1985
22. Mor V, Masterson-Allen S, Goldberg RJ, et al: Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc 33:585-589, 1985
23. Samet J, Hunt WC, Key C, et al: Choice of cancer therapy varies with age of patient. JAMA 255:3385-3388, 1986
24. Goble FC: Sex as a factor in metabolism, toxicity, and efficacy of pharmacodynamic and chemotherapeutic agents, in Garattini et al (eds): Advances in Pharmacology and Chemotherapy, vol 13. New York, NY, Academic Press, 1975, pp 174-252
25. Wilson K: Sex-related differences in drug disposition in man. Clin Pharmacokinet 9:189-202, 1984
26. Bennett BM, Twiddy DAS, Moffat JA, et al: Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood. Biochem Pharmacol 32:3729-3734, 1983
27. Tuchman M, Roemeling RV, Hrushesky WAM, et al: Dihydropyrimidine reductase activity in human blood mononuclear cells. Enzyme 42:15-24, 1989
28. Cohen SM: Difference in rates of response to chemotherapeutic agents between men and women with malignant melanoma. J Natl Cancer Invst 83:880, 1991